Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Methods In this phase 2 trial, patients with locally ad...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-02-01
coleção:	BMC Cancer
Assuntos:	PD-1 Monoclonal antibody Pucotenlimab HX008 Melanoma
Acesso em linha:	https://doi.org/10.1186/s12885-022-10473-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!